B 013
Alternative Names: B-013Latest Information Update: 21 Apr 2025
At a glance
- Originator Shanghai Pharmaceutical Group
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Triple negative breast cancer
- Phase II Breast cancer; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Ovarian cancer
Most Recent Events
- 11 Jul 2024 Phase-II clinical trials in Ovarian cancer (Combination therapy, Recurrent; Treatment-resistant) in China (IV) (NCT06434610)
- 30 May 2024 Shanghai Pharmaceutical Group plans a phase II trial for Ovarian cancer (Second-line therapy or greater, Recurrent, In adults, In the elderly) (IV), in June 2024 (NCT06434610)
- 06 Dec 2022 Phase-II/III clinical trials in Triple-negative-breast-cancer (First-line therapy, Combination therapy, Metastatic disease, Late-stage disease) in China (IV) (NCT05555706)